The poster describes nine-year interim results from a clinical study regarding MR-guided Focal Laser Ablation treatment of low-intermediate-risk localized prostate cancer (NCT02243033). Some of the treatments in the clinical study have been performed using the TRANBERG® laser applicator non-cooled, optimized for high-precision thermal ablation treatment.
Title: ”TRANSRECTALLY DELIVERED, OUTPATIENT MRI-GUIDED LASER FOCAL THERAPY OF PROSTATE CANCER: NINE YEAR INTERIM RESULTS” See the results here.
SPECIFIC AIMS: The study objective is to investigate the efficacy of using MR-guided laser focal therapy for MR visible prostate cancer utilizing a transrectal approach in an outpatient setting.
RATIONALE AND BACKGROUND: Lasers have been used for soft tissue necrotization for decades1. A commercially available MR-guided biopsy system allows the insertion of a laser fiber for insertion into biopsy proven cancerous lesions facilitating ablation of MR-visible tumors with real-time thermometry.
RESULTS: Under IRB-approved, HIPAA-compliant protocol, 146 men were treated. 228 cancer foci were treated. The total procedure time was between 1.5 and four hours. No serious adverse events or morbidity were reported.
DISCUSSION AND CONCLUSION: The data indicates that outpatient, transrectally delivered MRI-guided laser focal therapy for prostate cancer is both safe and feasible. In the current climate of cost-reduction and emphasis on minimally-invasive treatment of cancer, focal treatment of prostate cancer may be an attractive option. The precision and controllability achieved under MRI-guidance may have favorable results for cost effectiveness and quality of life without eliminating the possibility of whole-gland treatment in the patient’s future. The follow-up of these men will continue for twenty years as part of the IRB-approved clinical trial.